Why it matters: NRx Pharmaceuticals is returning to federal lobbying after a three-year hiatus just as its lead drug candidate approaches a critical regulatory milestone. The biotech company filed a New Drug Application in December 2024 for NRX-100, positioned as the first FDA-approved treatment for acute suicidal crises.
By the Numbers: Continental Strategy LLC registered to represent NRx Pharmaceuticals on April 27, 2025. The lobbying team includes Timothy M. Costa and Craig P. Carbone. Previously, NRx spent $30,000 with Vogel Group LLC from 2021-2022, focusing on Emergency Use Authorizations during COVID-19.
Broader Context: The Trump administration has implemented major FDA reforms in 2025. An executive order in May directed faster approval times for domestic pharmaceutical facilities. The new FDA leadership emphasizes accelerated pathways and supports CNS disorder treatments. Meanwhile, suicide remains a leading cause of death, with rates climbing 37% since 2000.
The Agenda: Continental Strategy will lobby on pharmacy-related matters. Specific issues weren’t detailed in the initial filing. This represents a shift from NRx’s previous focus on emergency authorizations to traditional pharmaceutical regulatory matters.
Competitive Landscape: No information was provided about other companies’ lobbying activities in this space.
Between The Lines: The timing aligns perfectly with NRx’s regulatory needs. Timothy M. Costa brings deep FDA experience from representing pharmaceutical clients on orphan drugs and post-approval issues. Craig P. Carbone served as Chief of Staff to Senator Rick Scott, who sits on the Senate HELP Committee overseeing FDA matters. NRx received expanded Fast Track designation in August 2025, accelerating its regulatory pathway.
The Bottom Line: NRx is positioning itself to navigate the new regulatory landscape as its suicide prevention drug advances through FDA review. The investment in experienced lobbyists with congressional connections suggests the company anticipates both opportunities and challenges ahead.
Spot something wrong? Report an issue with this article